Engelman R M, Pleet A B, Rousou J A, Flack J E, Deaton D W, Gregory C A, Pekow P S
Department of Surgery, Baystate Medical Center, Springfield, Mass. 01107, USA.
J Thorac Cardiovasc Surg. 1996 Dec;112(6):1622-32; discussion 1632-3. doi: 10.1016/S0022-5223(96)70021-1.
[corrected] A National Institutes of Health-funded clinical trial of patients undergoing coronary artery bypass randomized perfusate and myocardial preservation to cold, tepid, or warm temperatures. The goal of the trial was to evaluate neurologic function before and after operation (4 days and 1 month after operation) and to measure hematologic data for fibrinolytic potential.
The three groups comprised 116 patients who completed neurologic evaluation by means of the Mathew scale out of 130 entered into the trial (37 cold group, 50 tepid, and 43 warm). Twenty-five patients had complete hematologic studies done. All three groups were comparable before operation. The myocardial preservation protocol used blood cardioplegic solution at cold (8 degrees to 10 degrees C), tepid (32 degrees C), or warm (37 degrees C) temperature and the systemic perfusate temperature during cardiopulmonary bypass was 20 degrees (cold), 32 degrees C (tepid), or 37 degrees (warm).
Patients in the cold group had a longer duration of intubation and postoperative hospitalization and a slightly but significantly higher peak postoperative creatine kinase MB level than patients in the warm group. There were no deaths. There was deterioration in Mathew scale findings in all three groups, and no distinction could be made between groups. However, a significantly higher number in the cold group had an abnormal postoperative neurologic examination result that prompted computed tomographic scanning (18.9% cold, 2% tepid, 9.3% warm). A cerebrovascular accident was documented by computed tomographic scanning in 8.1%, 0%, and 4.7% of patients in the cold, tepid, and warm groups, respectively (not significant). Hematologic data documented significantly increased fibrinolytic potential in the warm group.
Perfusion temperature is a factor in recovery from cardiopulmonary bypass. Cold has more adverse neurologic sequelae that prompt computed tomographic scanning whereas warm has more activation of fibrinolytic potential. Tepid is the best temperature for optimizing recovery from cardiopulmonary bypass.
一项由美国国立卫生研究院资助的针对接受冠状动脉搭桥手术患者的临床试验,将灌注液和心肌保护措施随机分配至冷、温或热温度组。该试验的目的是评估手术前后(术后4天和1个月)的神经功能,并测量血液学数据以评估纤溶潜力。
三组共有130名患者进入试验,其中116名患者通过马修量表完成了神经功能评估(冷组37名,温组50名,热组43名)。25名患者进行了完整的血液学研究。三组在手术前具有可比性。心肌保护方案使用冷(8摄氏度至10摄氏度)、温(32摄氏度)或热(37摄氏度)温度的血液停搏液,体外循环期间的全身灌注液温度为20摄氏度(冷)、32摄氏度(温)或37摄氏度(热)。
冷组患者的插管时间和术后住院时间更长,术后肌酸激酶MB峰值水平略高于热组,但差异显著。无死亡病例。三组患者的马修量表评分均有所下降,且组间无差异。然而,冷组术后神经检查结果异常并因此进行计算机断层扫描的患者比例显著更高(冷组18.9%,温组2%,热组9.3%)。计算机断层扫描记录的脑血管意外发生率分别为冷组8.1%、温组0%、热组4.7%(无显著差异)。血液学数据显示热组的纤溶潜力显著增加。
灌注温度是体外循环恢复的一个因素。低温有更多不良神经后遗症,促使进行计算机断层扫描,而高温有更多纤溶潜力激活。温血灌注是优化体外循环恢复的最佳温度。